Close Menu

NEW YORK (GenomeWeb) – Danaher today announced a 5 percent year-over-year increase in its fourth quarter revenues, beating the consensus Wall Street estimate.

For the three months ended Dec. 31, 2018, the Washington-based conglomerate posted $5.36 billion in revenues, up from $5.09 billion in Q4 2017. Wall Street had expected, on average, revenues of $5.32 billion.

Non-GAAP core revenues were up almost 6 percent year over year, Danaher said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.